Precision BioSciences prices $125 million stock and pre-funded warrant offering
DTIL•Precision BioSciences priced an offering expected to raise approximately $125 million in gross proceeds, including 10,235,077 shares at $7.75 each and warrants for up to 5,893,964 shares at $7.749995 each.
1. Offering details
Precision BioSciences priced an underwritten offering of common stock and pre-funded warrants to raise approximately $125 million in gross proceeds. The offering includes 10,235,077 common shares at $7.75 per share and pre-funded warrants to purchase up to 5,893,964 common shares at $7.749995 each.
2. Use of proceeds
The closing is expected on or about November 6, 2026, subject to customary conditions. Net proceeds will fund research and development for PBGENE-HBV and PBGENE-DMD, working capital and general corporate purposes.
